We are live on
!
Find out more
II
Ishara Investments Portfolio holdings
AUM
$136M
This Fund
S&P 500
This Quarter
Est. Return
+20.83%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$30.5M
(+29%)
Cap. Flow
+$19.9M
Cap. Flow
% of AUM
14.62%
Top 10 Holdings %
Top 10 Hldgs %
50.98%
Holding
53
New
16
Increased
13
Reduced
8
Closed
12
Avg Time Held Equity + Options
1
quarter
Top 10 Avg Time Held Equity + Options
0.7
quarters
Top 20 Avg Time Held Equity + Options
0.9
quarters
Avg Time Held Equity only
1
quarter
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
0.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$6.31M |
| 2 |
Insmed
INSM
|
+$6.21M |
| 3 |
CRNX
Crinetics Pharmaceuticals
CRNX
|
+$5.33M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$4.97M |
| 5 |
Tonix Pharmaceuticals
TNXP
|
+$4.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.57M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$5.34M |
| 3 |
Axsome Therapeutics
AXSM
|
+$5.33M |
| 4 |
Verastem
VSTM
|
+$4.35M |
| 5 |
Arrowhead Research
ARWR
|
+$3.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Nektar Therapeutics
NKTR
$1.41B
| $1.86M | 1.37% |
+26,650
| New | +$1.95M |
2026 Q2
0 quarters
|
|
27
Scholar Rock
SRRK
$5.14B
| $1.69M | 1.24% |
30,750
-26,650
| -46% | -$1.29M |
2026 Q1
1 quarter
|
|
28
Enliven Therapeutics
ELVN
$3B
| $1.66M | 1.22% |
+32,800
| New | +$1.39M |
2026 Q2
0 quarters
|
|
29
Alnylam Pharmaceuticals
ALNY
$31.1B
| $1.54M | 1.13% |
5,125
| – | – |
2026 Q1
1 quarter
|
|
30
Beam Therapeutics
BEAM
$2.65B
| $1.41M | 1.03% |
41,000
-16,400
| -29% | -$495K |
2025 Q4
2 quarters
|
|
|
SION
31
Sionna Therapeutics
SION
$222M
| $1.35M | 0.99% |
123,000
+73,800
| +150% | +$2.95M |
2026 Q1
1 quarter
|
|
32
Oric Pharmaceuticals
ORIC
$1.24B
| $1.33M | 0.98% |
123,000
+20,500
| +20% | +$186K |
2025 Q4
2 quarters
|
|
33
NewAmsterdam Pharma
NAMS
$2.58B
| $1.25M | 0.92% |
36,900
| – | – |
2025 Q4
2 quarters
|
|
34
Vertex Pharmaceuticals
VRTX
$129B
| $1.22M | 0.9% |
+2,460
| New | +$1.09M |
2026 Q2
0 quarters
|
|
35
ARS Pharmaceuticals
SPRY
$421M
| $1.15M | 0.84% |
+143,490
| New | +$1.23M |
2026 Q2
0 quarters
|
|
36
Monopar Therapeutics
MNPR
$530M
| $1.14M | 0.84% |
+12,300
| New | +$761K |
2026 Q2
0 quarters
|
|
37
Erasca
ERAS
$5.61B
| $751K | 0.55% |
+41,000
| New | +$586K |
2026 Q2
0 quarters
|
|
38
Vera Therapeutics
VERA
$2.15B
| $440K | 0.32% |
10,250
-71,750
| -88% | -$2.67M |
2026 Q1
1 quarter
|
|
39
Immatics
IMTX
$1.13B
| $311K | 0.23% |
30,750
-123,000
| -80% | -$1.3M |
2025 Q4
2 quarters
|
|
|
MREO
40
Mereo BioPharma
MREO
$55.9M
| $244K | 0.18% |
+768,750
| New | +$231K |
2026 Q2
0 quarters
|
|
41
Gossamer Bio
GOSS
$56.9M
| $135K | 0.1% |
10,250
| – | – |
2026 Q1
1 quarter
|
|
42
Ardelyx
ARDX
$847M
| – | – |
-451,000
| Closed | -$2.7M | – |
|
|
43
Arrowhead Research
ARWR
$8.86B
| – | – |
-55,350
| Closed | -$3.47M | – |
|
|
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-82,000
| Closed | -$2.03M | – |
|
45
Edgewise Therapeutics
EWTX
$4.24B
| – | – |
-49,200
| Closed | -$1.55M | – |
|
|
FOLD
46
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-369,000
| Closed | -$5.34M | – |
|
47
IDEAYA Biosciences
IDYA
$3.48B
| – | – |
-24,600
| Closed | -$820K | – |
|
|
KALV
48
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-276,750
| Closed | -$5.57M | – |
|
49
Ligand Pharmaceuticals
LGND
$6.02B
| – | – |
-8,200
| Closed | -$1.64M | – |
|
50
MoonLake Immunotherapeutics
MLTX
$921M
| – | – |
-174,250
| Closed | -$3.25M | – |
|
Similar funds
SB
WFA
RC
GBFP
RCWM
KCA
HMS
TH
Ishara Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Ishara Investments held 53 positions worth $136M, up 29% from $106M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Ishara Investments deployed $19.9M of net new capital in Q2 2026, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 51,250 shares worth $5.46M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.
On the sell side, the largest reduction was Axsome Therapeutics, an estimated $5.33M trimmed.
- Ishara Investments's largest Q2 2026 buy was Insmed: 51,250 shares worth $5.46M.
- Ishara Investments added most to Acadia Pharmaceuticals in Q2 2026, an estimated $6.31M increase.
- Ishara Investments's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.33M.
- Ishara Investments fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $5.57M.
- Ishara Investments's ten largest holdings make up 51% of its $136M portfolio in Q2 2026.
- Ishara Investments opened 16 new positions and closed 12 in Q2 2026.
- Ishara Investments's portfolio value rose 29% quarter-over-quarter to $136M.
Based on Ishara Investments's 13F filing for Q2 2026, filed 14 Aug 2026.